checkAd
    Startseite > Aktien > AlloVir > Nachrichten
    AlloVir
    Aktie
    ISIN: US0198181036 WKN: A2QAMR SYM: ALVR Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    0,7612
     
    USD
    +0,16 %
    +0,0012 USD
    Letzter Kurs 15.06.24 Nasdaq
    Geldkurs
    14.06.24
    0,7599
     
    USD
    100 STK
    Briefkurs
    14.06.24
    0,7612
     
    USD
    1.800 STK

    AlloVir Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    ALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALVR
    18.03.24 · Business Wire (engl.) · AlloVir
    ALLOVIR INVESTOR ALERT: Kirby McInerney LLP Notifies AlloVir, Inc. (ALVR) Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
    12.02.24 · Business Wire (engl.) · AlloVir
    ALVR Stock News: Investors with Large Losses Should Contact Robbins LLP for Information About the Class Action Against AlloVir, Inc.
    06.02.24 · Business Wire (engl.) · AlloVir
    ALVR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
    30.01.24 · Business Wire (engl.) · AlloVir
    AlloVir, Inc. (ALVR) Investor Alert: Robbins LLP Reminds Stockholders of Class Action Against AlloVir, Inc.
    25.01.24 · Business Wire (engl.) · AlloVir
    ALVR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
    23.01.24 · Business Wire (engl.) · AlloVir
    Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of AlloVir, Inc. (ALVR) Investors
    22.01.24 · Business Wire (engl.) · AlloVir
    ROSEN, A LONGSTANDING LAW FIRM, Encourages AlloVir, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALVR
    22.01.24 · Business Wire (engl.) · AlloVir
    AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
    22.12.23 · globenewswire · AlloVir
    AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
    16.11.23 · Business Wire (engl.) · AlloVir
    AlloVir Reports Third Quarter 2023 Financial Results
    02.11.23 · Business Wire (engl.) · AlloVir
    AlloVir to Present at Upcoming Investor Conferences
    28.08.23 · Business Wire (engl.) · AlloVir